The recent West African Ebola virus pandemic, which affected >28,000 individuals increased 23 interest in anti-Ebolavirus vaccination programs. Here, we systematically analyzed the 24 requirements for a prophylactic vaccination program based on the basic reproductive number 25 (R0, i.e. the number of secondary cases that result from an individual infection). Published R0 26 values were determined by a systematic literature research and ranged from 0.37 to 20. R0s 27
Methods

73
Ebolavirus nomenclature 74 The nomenclature in this manuscript follows the recommendations of Kuhn Identification of studies that report on the basic reproductive number (R0) of 80
Ebolaviruses 81
To identify scientific articles that have calculated the basic reproductive number (R0) for 82
Ebolaviruses, we performed a literature search using PubMed 83 (www.ncbi.nlm.nih.gov/pubmed) for the search term combinations "Ebola R0", "Ebola basic 84 reproductive number", and "Ebola basic reproduction number" (retrieved on 29 th September 85 2017). 86 87
Determination of herd immunity thresholds and their implications for Ebolavirus 88 diseases prevention strategies 89
Based on the basic reproductive number R0, i.e. the number of secondary cases that result 90 from an individual infection, the herd immunity threshold (Ic) was calculated using equation 91 1 92 Ic = 1 -(1/R0) (eqn 1) 93 94 where Ic indicates the proportion of a society that needs to be protected from infection to 95 achieve herd immunity. Next, the critical vaccination coverage (Vc) that is needed to provide 96 herd immunity was determined by including the vaccine effectiveness (E) using equation 2 97 Vc = Ic / E = [1 -(1/R0)]/ E (eqn 2) 98 (9-13). 99 100 101
Results
103
Basic reproductive number (R0) values for Ebolaviruses 104
The PubMed search for "Ebola R0" provided 18 hits, the search for "Ebola basic 105
reproductive number" provided 42 hits, and the search for "Ebola basic reproduction 106 number" provided 35 hits ( Figure 1 ; Data Sheet 1). After removal of the overlaps and 107 inclusion of an additional article (identified from the reference list of (12)) this resulted in 51 108 articles, 35 of which provided relevant information on Ebolavirus R0 values ( Figure 1 At an R0 of 4, the Ic (eqn 1) is 75%, which means that 75% of a population need to be 140 immune to provide herd immunity (Figure 2A , Data Sheet 3). The Ic further rises to 80% at 141 an R0 of 5, to 90% at an R0 of 10, and to 95% R0 of 20 ( Figure 2A , Data Sheet 3). This shows 142 that high proportions of a population need to be immune to establish effective herd immunity. 143 144
Critical vaccine coverage (Vc) 145
As there is currently no approved vaccine for the prevention of Ebolavirus disease, we 146 calculated a range of Vc (eqn 2) scenarios that reflect the efficacy range covered by approved 147
vaccines. Attenuated replication-competent measles virus vaccines have been reported to 148 protect up to 95% of individuals from disease after one dose, which increased to up to 99% 149 after a second dose (28). The efficacy of varicella zoster virus vaccines, another attenuated 150 replication-competent vaccine, was recently calculated to be 81.9% after one dose and 94.4% 151 after two doses (29). Inactivated seasonal influenza virus split vaccines have been reported to 152 have a substantially lower efficiency of 50-60% (30-32). Hence, we considered a Vc range 153 between 50% and 100% ( Figure 2B , Data Sheet 3). Vaccines, which provide high protection 154
(ideally after a single vaccination), and high vaccination rates are required to prevent 155
Ebolavirus outbreaks. If we assume an R0 of 4 and a vaccination efficacy E of 90%, more 156 than 80% of a population need to be vaccinated to establish herd immunity. If the R0 rises to 157 5 a vaccine coverage of 80% would be required, even if a vaccine with 100% efficacy was 158 available ( Figure 2B , Data Sheet 3). 159 160
Discussion
162
We performed an analysis of the Ebolavirus vaccine requirements to achieve the Vc needed 163 for prophylactic mass vaccination programs. Vaccines need to prevent Ebolavirus outbreaks 164 that spread at an R0≥4, which reflects the critical early outbreak phases prior to the 165 implementation of control measures and superspreading events (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) lack of equipment and trained medical specialists, and cultural and language barriers (48,49). 214 215
In conclusion, the achievement of a Vc of 75% that is necessary to prevent an outbreak that 216 spreads with an R0 of 4 with a vaccine that has an efficacy of 100% is currently unrealistic 217 because of limited vaccine acceptance in the affected populations and because of financial 218 and logistical challenges. In addition, concurrent diseases such as HIV and cancer, along with 219 potential side effects of vaccination, may remove significant numbers of potential vaccinees 220 (5,50 
